Clovis Oncology, Inc. (CLVS): Price and Financial Metrics
CLVS Price/Volume Stats
| Current price | $0.08 | 52-week high | $3.32 |
| Prev. close | $0.09 | 52-week low | $0.08 |
| Day low | $0.08 | Volume | 24,516,400 |
| Day high | $0.10 | Avg. volume | 8,875,886 |
| 50-day MA | $0.59 | Dividend yield | N/A |
| 200-day MA | $1.29 | Market Cap | 11.77M |
CLVS Stock Price Chart Interactive Chart >
Clovis Oncology, Inc. (CLVS) Company Bio
Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international markets. Clovis Oncology targets development programs at specific subsets of cancer populations, and simultaneously develops diagnostic tools that direct a compound in development to the population that is most likely to benefit from its use. The company was founded in 2009 and is based in Boulder, Colorado.
Latest CLVS News From Around the Web
Below are the latest news stories about CLOVIS ONCOLOGY INC that investors may wish to consider to help them evaluate CLVS as an investment opportunity.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on WednesdayWe're starting off the day with an overview of the biggest pre-market stock movers traders need to know about on Wednesday! |
CLVS Stock Alert: What to Know as Clovis Oncology Files for BankruptcyClovis Oncology (CLVS) stock is on the move Monday as investors react to the pharmaceutical company filing for bankruptcy protection. |
Clovis Enters Bankruptcy With Deal to Sell Cancer-Drug Candidate to NovartisClovis Oncology, maker of ovarian cancer drug Rubraca, has filed for chapter 11 and proposed selling a separate therapy to a Novartis affiliate. |
Clovis (CLVS) Files for Bankruptcy Amid Lack of Financial AidRecent regulatory developments force Clovis (CLVS) to file for bankruptcy. The company inks a stalking horse agreement with Novartis for one of its pipeline candidates. |
Clovis Plans to Sell Cancer Drug to Novartis in Bankruptcy Deal(Bloomberg) -- Clovis Oncology Inc. filed for bankruptcy and plans to sell its experimental cancer drug at an auction with Novartis Innovative Therapies making a binding, opening bid worth as much as $681 million.Most Read from BloombergChina’s Rapid Covid Reversal Sparks Whiplash as Cases SurgeUS Says Scientists Make Breakthrough in Nuclear Fusion EnergyElon Musk Is Ruining Trump’s Presidential CampaignUS Stocks Start Fed Week Higher as CPI Data Loom: Markets WrapFed’s Message That Rates Will S |
CLVS Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | N/A |
| 3-year | -98.69% |
| 5-year | -99.58% |
| YTD | N/A |
| 2023 | N/A |
| 2022 | 0.00% |
| 2021 | -43.54% |
| 2020 | -53.96% |
| 2019 | -41.95% |
Continue Researching CLVS
Here are a few links from around the web to help you further your research on Clovis Oncology Inc's stock as an investment opportunity:Clovis Oncology Inc (CLVS) Stock Price | Nasdaq
Clovis Oncology Inc (CLVS) Stock Quote, History and News - Yahoo Finance
Clovis Oncology Inc (CLVS) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...